Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1990 Sep;64(9):4540–4548. doi: 10.1128/jvi.64.9.4540-4548.1990

The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).

P R Kinchington 1, P Ling 1, M Pensiero 1, B Moss 1, W T Ruyechan 1, J Hay 1
PMCID: PMC247925  PMID: 2166829

Abstract

Many characteristics of the putative protein encoded by varicella-zoster virus (VZV) open reading fram (ORF) 14 indicate that it is a glycoprotein, which has been designated gpV. To identify the protein products of the gene, the coding sequences were placed under the control of the vaccinia virus p7.5 promoter and recombinant vaccinia viruses were constructed. Heterogeneous polypeptides with molecular weights of 95,000 to 105,000 (95K to 105K polypeptides) were expressed in cells infected by a vaccinia virus recombinant (vKIP5) containing ORF 14 from VZV Scott but were not expressed by control vaccinia viruses. These polypeptides were recognized by antibodies present in human sera that contained high levels of anti-VZV antibodies. Conversely, antisera raised in rabbits inoculated with vKIP5 reacted specifically with heterogeneous 95K to 105K polypeptides present in VZV Scott-infected but not uninfected cells; these polypeptides show a patchy plasma membrane fluorescence pattern in VZV Scott-infected cells. These same antisera neutralized VZV strain Scott infectivity in the absence of complement. Endoglycosidase F treatment of isolated gpV polypeptides and tunicamycin treatment of cells infected with the vKIP5 recombinant indicated that the polypeptides were glycosylated. Three sets of data imply that the VZV strain Oka, which has been used to produce a live attenuated virus vaccine, accumulates low levels of gpV polypeptides relative to wild-type strains: (i) blocking of antibodies in human sera with excess VZV Oka-infected cell antigen yielded residual antibodies which were reactive with the 95K to 105K gpV polypeptides expressed in cells infected by VZV strain Scott and by the vKIP5 vaccinia virus recombinant, but not with Oka-infected cell polypeptides; (ii) antisera raised to vKIP5 detected very low levels of reactive polypeptides made in VZV Oka-infected cells and neutralized VZV Oka virus much less efficiently than VZV Scott; and (iii) comparisons of the reactivity of sera from live attenuated virus vaccine vaccinees with sera derived from patients recovering from wild-type infections indicated greatly reduced levels of gpV-specific antibodies in some vaccinees.

Full text

PDF
4540

Images in this article

4543Image
on p.4543
4543Image
on p.4543
4544Image
on p.4544
4544Image
on p.4544
4544Image
on p.4544
4545Image
on p.4545
4545Image
on p.4545
4546Image
on p.4546

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brunell P. A., Novelli V. M., Lipton S. V., Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics. 1988 Jun;81(6):779–784. [PubMed] [Google Scholar]
  2. Cabirac G., Gilden D., Wellish M., Vafai A. Expression of varicella-zoster virus glycoprotein I in cells infected with a vaccinia virus recombinant. Virus Res. 1988 May;10(2-3):205–213. doi: 10.1016/0168-1702(88)90016-0. [DOI] [PubMed] [Google Scholar]
  3. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol. 1985 Dec;5(12):3403–3409. doi: 10.1128/mcb.5.12.3403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davison A. J., Edson C. M., Ellis R. W., Forghani B., Gilden D., Grose C., Keller P. M., Vafai A., Wroblewska Z., Yamanishi K. New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol. 1986 Mar;57(3):1195–1197. doi: 10.1128/jvi.57.3.1195-1197.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davison A. J., Scott J. E. The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986 Sep;67(Pt 9):1759–1816. doi: 10.1099/0022-1317-67-9-1759. [DOI] [PubMed] [Google Scholar]
  6. Davison A. J., Waters D. J., Edson C. M. Identification of the products of a varicella-zoster virus glycoprotein gene. J Gen Virol. 1985 Oct;66(Pt 10):2237–2242. doi: 10.1099/0022-1317-66-10-2237. [DOI] [PubMed] [Google Scholar]
  7. Draper K. G., Costa R. H., Lee G. T., Spear P. G., Wagner E. K. Molecular basis of the glycoprotein-C-negative phenotype of herpes simplex virus type 1 macroplaque strain. J Virol. 1984 Sep;51(3):578–585. doi: 10.1128/jvi.51.3.578-585.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dubey L., Steinberg S. P., LaRussa P., Oh P., Gershon A. A. Western blot analysis of antibody to varicella-zoster virus. J Infect Dis. 1988 May;157(5):882–888. doi: 10.1093/infdis/157.5.882. [DOI] [PubMed] [Google Scholar]
  9. Eberle R., Courtney R. J. Preparation and characterization of specific antisera to individual glycoprotein antigens comprising the major glycoprotein region of herpes simplex virus type 1. J Virol. 1980 Sep;35(3):902–917. doi: 10.1128/jvi.35.3.902-917.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Edson C. M., Hosler B. A., Poodry C. A., Schooley R. T., Waters D. J., Thorley-Lawson D. A. Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material. Virology. 1985 Aug;145(1):62–71. doi: 10.1016/0042-6822(85)90201-6. [DOI] [PubMed] [Google Scholar]
  11. Edson C. M., Hosler B. A., Respess R. A., Waters D. J., Thorley-Lawson D. A. Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein. J Virol. 1985 Oct;56(1):333–336. doi: 10.1128/jvi.56.1.333-336.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Forghani B., Dupuis K. W., Schmidt N. J. Varicella-zoster viral glycoproteins analyzed with monoclonal antibodies. J Virol. 1984 Oct;52(1):55–62. doi: 10.1128/jvi.52.1.55-62.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Forghani B., Schmidt N. J., Myoraku C. K., Gallo D. Serological reactivity of some monoclonal antibodies to varicella-zoster virus. Arch Virol. 1982;73(3-4):311–317. doi: 10.1007/BF01318084. [DOI] [PubMed] [Google Scholar]
  14. Gabel C. A., Dubey L., Steinberg S. P., Sherman D., Gershon M. D., Gershon A. A. Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J Virol. 1989 Oct;63(10):4264–4276. doi: 10.1128/jvi.63.10.4264-4276.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gershon A. A. Live attenuated varicella vaccine. Annu Rev Med. 1987;38:41–50. doi: 10.1146/annurev.me.38.020187.000353. [DOI] [PubMed] [Google Scholar]
  16. Grose C., Edwards D. P., Friedrichs W. E., Weigle K. A., McGuire W. L. Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun. 1983 Apr;40(1):381–388. doi: 10.1128/iai.40.1.381-388.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Grose C., Jackson W., Traugh J. A. Phosphorylation of varicella-zoster virus glycoprotein gpI by mammalian casein kinase II and casein kinase I. J Virol. 1989 Sep;63(9):3912–3918. doi: 10.1128/jvi.63.9.3912-3918.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Homa F. L., Purifoy D. J., Glorioso J. C., Levine M. Molecular basis of the glycoprotein C-negative phenotypes of herpes simplex virus type 1 mutants selected with a virus-neutralizing monoclonal antibody. J Virol. 1986 May;58(2):281–289. doi: 10.1128/jvi.58.2.281-289.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Keller P. M., Davison A. J., Lowe R. S., Bennett C. D., Ellis R. W. Identification and structure of the gene encoding gpII, a major glycoprotein of varicella-zoster virus. Virology. 1986 Jul 15;152(1):181–191. doi: 10.1016/0042-6822(86)90383-1. [DOI] [PubMed] [Google Scholar]
  20. Keller P. M., Neff B. J., Ellis R. W. Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes. J Virol. 1984 Oct;52(1):293–297. doi: 10.1128/jvi.52.1.293-297.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kinchington P. R., Remenick J., Ostrove J. M., Straus S. E., Ruyechan W. T., Hay J. Putative glycoprotein gene of varicella-zoster virus with variable copy numbers of a 42-base-pair repeat sequence has homology to herpes simplex virus glycoprotein C. J Virol. 1986 Sep;59(3):660–668. doi: 10.1128/jvi.59.3.660-668.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol. 1987 Aug 20;196(4):947–950. doi: 10.1016/0022-2836(87)90418-9. [DOI] [PubMed] [Google Scholar]
  23. Mackett M., Smith G. L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984 Mar;49(3):857–864. doi: 10.1128/jvi.49.3.857-864.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Montalvo E. A., Parmley R. T., Grose C. Structural analysis of the varicella-zoster virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide moieties. J Virol. 1985 Mar;53(3):761–770. doi: 10.1128/jvi.53.3.761-770.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Namazue J., Campo-Vera H., Kitamura K., Okuno T., Yamanishi K. Processing of virus-specific glycoproteins of varicella zoster virus. Virology. 1985 May;143(1):252–259. doi: 10.1016/0042-6822(85)90112-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Okuno T., Yamanishi K., Shiraki K., Takahashi M. Synthesis and processing of glycoproteins of Varicella-Zoster virus (VZV) as studied with monoclonal antibodies to VZV antigens. Virology. 1983 Sep;129(2):357–368. doi: 10.1016/0042-6822(83)90175-7. [DOI] [PubMed] [Google Scholar]
  27. Roberts C. R., Weir A. C., Hay J., Straus S. E., Ruyechan W. T. DNA-binding proteins present in varicella-zoster virus-infected cells. J Virol. 1985 Jul;55(1):45–53. doi: 10.1128/jvi.55.1.45-53.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ruyechan W. T., Casey T. A., Reinhold W., Weir A. C., Wellman M., Straus S. E., Hay J. Distribution of G + C-rich regions in varicella-zoster virus DNA. J Gen Virol. 1985 Jan;66(Pt 1):43–54. doi: 10.1099/0022-1317-66-1-43. [DOI] [PubMed] [Google Scholar]
  29. Sim C., Watson D. H. The role of type specific and cross reacting structural antigens in the neutralization of herpes simplex virus types 1 and 2. J Gen Virol. 1973 May;19(2):217–233. doi: 10.1099/0022-1317-19-2-217. [DOI] [PubMed] [Google Scholar]
  30. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  31. Straus S. E., Aulakh H. S., Ruyechan W. T., Hay J., Casey T. A., Vande Woude G. F., Owens J., Smith H. A. Structure of varicella-zoster virus DNA. J Virol. 1981 Nov;40(2):516–525. doi: 10.1128/jvi.40.2.516-525.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974 Nov 30;2(7892):1288–1290. doi: 10.1016/s0140-6736(74)90144-5. [DOI] [PubMed] [Google Scholar]
  33. Vafai A., Jensen K., Kubo R. Existence of similar antigenic-sites on varicella-zoster virus gpI and gpIV. Virus Res. 1989 Aug;13(4):319–336. doi: 10.1016/0168-1702(89)90077-4. [DOI] [PubMed] [Google Scholar]
  34. Vafai A., Wroblewska Z., Wellish M., Green M., Gilden D. Analysis of three late varicella-zoster virus proteins, a 125,000-molecular-weight protein and gp1 and gp3. J Virol. 1984 Dec;52(3):953–959. doi: 10.1128/jvi.52.3.953-959.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wroblewska Z., Gilden D., Green M., Devlin M., Vafai A. Affinity-purified varicella-zoster virus glycoprotein gp1/gp3 stimulates the production of neutralizing antibody. J Gen Virol. 1985 Aug;66(Pt 8):1795–1799. doi: 10.1099/0022-1317-66-8-1795. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES